Literature DB >> 2340945

Renal excretory actions of furosemide, of hydrochlorothiazide and of the vasodilator flosequinan in healthy subjects.

W P Leary1, A J Reyes, R D Wynne, K van der Byl.   

Abstract

The responses of urine and urinary solute outputs and flows to single doses of 80 mg furosemide, 25 mg hydrochlorothiazide, and 100 or 200 mg flosequinan were investigated in healthy subjects using a double-blind, randomized, crossover design. Treatment days were separated by 7 days. Volumes of urine passed between 0 and 3, 3 and 6, 6 and 9, 9 and 12, and 12 and 24 h after drug administration were determined and urinary concentrations of chloride, sodium, potassium, calcium, magnesium, phosphate, zinc, urate, urea and creatinine were measured. Venous blood was taken before and 6 and 24 h after dosing and the serum was analysed for the same solutes as urine. Excretions of urine and urinary solutes accumulated at the end of each collection period after each formulation were fitted by the UY function, whose derivative provided corresponding flows as functions of time. Instantaneous renal clearances of solutes 6 and 24 h after dosing were evaluated from the flows. This approach showed that 80 mg furosemide and 25 mg hydrochlorothiazide were equipotent 24-h natriuretics. Rapid urinary responses which then rebounded compared with the control responses were produced by 80 mg furosemide, whereas changes after 25 mg hydrochlorothiazide were smooth. Neither 100 or 200 mg flosequinan showed any important effect on urinary excretion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2340945     DOI: 10.1177/030006059001800207

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  14 in total

Review 1.  Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives.

Authors:  Klaus K Witte; Andrew L Clark
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.214

2.  Enteral zinc supplementation and growth in extremely-low-birth-weight infants with chronic lung disease.

Authors:  Ala K Shaikhkhalil; Jennifer Curtiss; Teresa D Puthoff; Christina J Valentine
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-02       Impact factor: 2.839

3.  Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia.

Authors:  Hyon K Choi; Natalie McCormick; Na Lu; Sharan K Rai; Chio Yokose; Yuqing Zhang
Journal:  Arthritis Rheumatol       Date:  2019-12-03       Impact factor: 10.995

Review 4.  Clinicopharmacological reappraisal of the potency of diuretics.

Authors:  A J Reyes; W P Leary
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 5.  Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations.

Authors:  A J Reyes; W P Leary
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 6.  Do diuretics cause magnesium deficiency?

Authors:  D L Davies; R Fraser
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

Review 7.  Loop diuretics versus others in the treatment of congestive heart failure after myocardial infarction.

Authors:  A J Reyes
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

8.  Serum zinc values in children with congenital heart disease.

Authors:  W E Sadoh; A E Sadoh
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

Review 9.  Effects of diuretics on outputs and flows of urine and urinary solutes in healthy subjects.

Authors:  A J Reyes
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.